AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 221 min read$FDMT

Bizily Scott sold $22K of FDMT

Bizily Scott (Chief Legal Officer) sold 1,635 shares of 4D Molecular Therapeutics, Inc. (FDMT) at $13.65 on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bizily Scott
Published Sep 22, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 10:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FDMT
Neutral
high confidence
Mentioned
$FDMT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FDMTNeutralLow
01

Why it matters

The disclosed sale is minor and unlikely to move the stock, but it provides transparency for investors monitoring insider activity.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical data could outweigh the impact of this minor transaction.

Relevance 2/10Novelty 3/10Timing: post filing 2026‑09‑22

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$FDMTNeutralHigh confidence
Context

Chief Legal Officer sold 1,635 shares for $22,317.75 via a 10b5‑1 plan on 2026‑09‑16.

Expected impact

No material price move expected; possible slight dip.

Evidence & confidence

The transaction size ($22k) is trivial relative to market cap; insider is selling under a pre‑arranged plan, indicating no urgent negative signal.

Market effects

Sector

None; biotech sector unchanged by this small sale.

Regional

No regional effect.

Global

Not applicable.

Counterpoint

What could challenge this read

If the insider sale signals confidence in future upside, the market could ignore the sell‑off.

Key entities

  • Person
    Bizily Scott

    Chief Legal Officer of 4D Molecular Therapeutics, Inc.

  • Company
    4D Molecular Therapeutics, Inc.

    Biotech firm developing molecular therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FDMT insider trading history →

Related articles

SEP 28
$FDMTMedAI 8/10

4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical…

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 28, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (“DME”). The

SEC EDGAR 8-K2 min
AUG 17
$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

rttnews.com7 min
AUG 13
$FDMTMed

4D Molecular Therapeutics, Inc. (FDMT): Results of Operations and Financial Condition

4D Molecular Therapeutics, Inc. (FDMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 • Prese

SEC EDGAR 8-K6 min